Objectives The detection rate of small pulmonary nodules has recently increased and new
techniques have been developed to improve diagnostic yield. The IASLC/ATS/ERS …

Background Lymphovascular invasion (LVI) has not been included in the tumor‐node‐
metastasis (TNM) staging manual of non‐small‐cell lung cancer (NSCLC). We aimed to …

Objective To determine long-term survival of visceral pleural invasion (VPI) and
parenchymal invasion (PAI)(angiolymphatic and/or vascular) on survival of NSCLCs less …

Background Lymphovascular invasion (LVI) is an invasive biologic behavior that affects the
treatment and prognosis of patients with early-stage lung cancer. This study aimed to identify …

Objectives This study explored the prognostic significance and adjuvant chemotherapy
benefits in resected patients with stage I non–small cell lung cancer with lymphovascular …

Introduction Lymphovascular invasion (LVI) is a known adverse prognostic factor for early-
stage non–small-cell lung cancer (NSCLC). Nonetheless, the prognostic effect of LVI on …

Background: The Glasgow Prognostic Score (GPS), which consists of albumin and C-
reactive protein (CRP), may predict overall survival (OS) in cancer patients. The aim of this …

Rationale and Objectives This study aims to develop and validate a nomogram integrating
clinical-CT and radiomic features for preoperative prediction of microvascular invasion (MVI) …

Objectives Approximately 15% of stage I lung adenocarcinomas will recur despite adequate
surgical therapy. Adjuvant therapy may benefit specific high-risk subsets; however, it is …

Background Lymphovascular invasion (LVI) is an adverse prognostic feature in resected
stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic …